MP06-19 ANTI-TUMOR EFFECT IN BLADDER CANCER MODEL OF TUMOR VASCULATURE-TARGETED 10 B DELIVERY MEDIATED BORON NEUTRON CAPTURE THERAPY

Abstract

You have accessJournal of UrologyCME1 May 2022MP06-19 ANTI-TUMOR EFFECT IN BLADDER CANCER MODEL OF TUMOR VASCULATURE-TARGETED 10B DELIVERY MEDIATED BORON NEUTRON CAPTURE THERAPY Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Taku Yoshiya, Tsuyoshi Uemura, Takehiro Ishizu, Minoru Suzuki, Shingo Hachinohe, Shintaro Ishiyama, Motohiro Nonaka, Michiko N. Fukuda, and Chikara Ohyama Tohru YoneyamaTohru Yoneyama More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Mihoko Sutoh YoneyamaMihoko Sutoh Yoneyama More articles by this author , Taku YoshiyaTaku Yoshiya More articles by this author , Tsuyoshi UemuraTsuyoshi Uemura More articles by this author , Takehiro IshizuTakehiro Ishizu More articles by this author , Minoru SuzukiMinoru Suzuki More articles by this author , Shingo HachinoheShingo Hachinohe More articles by this author , Shintaro IshiyamaShintaro Ishiyama More articles by this author , Motohiro NonakaMotohiro Nonaka More articles by this author , Michiko N. FukudaMichiko N. Fukuda More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002523.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: p-Boronophenylalanine (10BPA) is a powerful 10B drug used in current clinical trials of BNCT. For BNCT to be successful, a high (500 mg/kg) dose of 10BPA must be administered over a few hours. Here, we report BNCT efficacy after rapid, ultralow-dose administration of either tumor vasculature-specific annexin A1-targeting IFLLWQR (IF7)-conjugated 10BPA or borocaptate sodium (10BSH). METHODS: IF7 conjugates of either 10B drugs intravenously injected into MBT2 bladder tumor-bearing mice and biodistribution of 10B in tumors and normal organs analyzed by prompt gamma-ray analysis. Therapeutic effect of IF7-10B drug-mediated BNCT was assessed by either MBT2 bladder tumor bearing C3H/He mice and YTS-1 tumor bearing nude mice. RESULTS: Intravenous injection of IF7C conjugates of either 10B drugs into MBT2 bladder tumor-bearing mice promoted rapid 10B accumulation in tumor tissues and suppressed tumor growth. Moreover, multiple treatments at ultralow (10–20 mg/kg) doses of IF7-10B drug-mediated BNCT significantly suppressed tumor growth in a mouse model of human YTS-1 bladder cancer, with increased Anxa1 expression in tumors and infiltration by CD8-positive lymphocytes. Our findings suggest BNCT treatment induces an immune response by the host against tumor cells, triggering a strong cytotoxic reaction and also inflammatory and immune responses that increase after BNCT upregulate Anxa1 expression in tumor tissues. Moreover, we hypothesize that if the first BNCT treatment upregulates Anxa1 in tumor tissues due to an inflammatory response or induced immunogenicity, more effective 10B accumulation in tumor tissues might occur following the second injection of IF7-10B drugs. Thus, multiple ultralow doses of IF7-10B drug-mediated BNCT likely boost BNCT therapeutic potential. CONCLUSIONS: We conclude that IF7 serves as an efficient 10B delivery vehicle by targeting bladder tumor tissues via the tumor vasculature and could serve as a relevant vehicle for BNCT drugs. Source of Funding: This study was supported by a Center of Innovation program grant for the young scientist collaborative research fund project (no. R02W16) from the Japan Science and Technology Agency and supported by the Japan Society for the Promotion of Science KAKENHI (grants nos. 17K11119, 20K09517, and 19H05556). The study was also supported by the Kobayashi Foundation for Cancer Research and by the Aomori Prefecture Quantum Science Center © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e84 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tohru Yoneyama More articles by this author Shingo Hatakeyama More articles by this author Mihoko Sutoh Yoneyama More articles by this author Taku Yoshiya More articles by this author Tsuyoshi Uemura More articles by this author Takehiro Ishizu More articles by this author Minoru Suzuki More articles by this author Shingo Hachinohe More articles by this author Shintaro Ishiyama More articles by this author Motohiro Nonaka More articles by this author Michiko N. Fukuda More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement PDF DownloadLoading ...